Most notably S1PR1 modulators (Fingolimod, MT-1303, Ozanimod) are tested or already in clinical use for treating inflammation-driven diseases such as multiple sclerosis, inflammatory bowel disease and psoriasis (223). The gene discussed is S1PR1; the disease is inflammatory bowel disease.